1University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey; 2University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Department of Family Medicine, Istanbul, Turkey.
Acta Clin Croat. 2022 Feb;60(3):361-366. doi: 10.20471/acc.2021.60.03.04.
Synthetic cannabinoid (locally named 'Bonzai' in Turkey) use is increasing worldwide (especially among people with low income). One of its harmful adverse effects is an increase in serum levels of muscle enzymes (i.e., creatine kinase [CK]). The aim of this study was to determine the prevalence of Bonzai use in patients admitted with elevated CK levels and to compare the 1-month survival status of Bonzai users with that of non-Bonzai users. This retrospective study was conducted on a total of 468 patients, median (min-max) age 48±22 (18-93) years. It was found that 10.68% (n=50) of the patients presenting with elevated CK levels were using Bonzai (group 1), while the remaining 418 (89.32%) patients were non-Bonzai users (group 2). Median age was higher in group 2 as compared with group 1 (p=0.001). In group 1, the predominance of male (M) over female (F) patients was interestingly high, yielding a F:M ratio of 1/49 (χ=110.03, p<0.001). The prevalence of Bonzai use among patients admitted to our center with elevated CK levels was 10.68%. The Bonzai group patients were younger and mostly males, and none of them died at 1 month of admission. These findings may help in the management of such clinical conditions and could be a pathfinder for further studies in this field.
合成大麻素（在土耳其当地名为“Bonzai”）的使用正在全球范围内增加（尤其是在低收入人群中）。其有害的不良影响之一是血清肌肉酶水平升高（即肌酸激酶[CK]）。本研究旨在确定因 CK 水平升高而住院的患者中使用 Bonzai 的流行率，并比较 Bonzai 使用者和非 Bonzai 使用者的 1 个月生存率。这是一项回顾性研究，共纳入 468 例患者，中位（最小-最大）年龄 48±22（18-93）岁。结果发现，10.68%（n=50）CK 水平升高的患者使用了 Bonzai（组 1），而其余 418 例（89.32%）患者为非 Bonzai 使用者（组 2）。与组 2 相比，组 1 的中位年龄更高（p=0.001）。有趣的是，在组 1 中，男性（M）患者明显多于女性（F）患者，男女比例为 1/49（χ=110.03，p<0.001）。在因 CK 水平升高而入住我院的患者中，Bonzai 的使用率为 10.68%。Bonzai 组患者年龄较小，且大多数为男性，在入院后 1 个月内无人死亡。这些发现可能有助于此类临床情况的管理，并可能为该领域的进一步研究提供线索。
